Lydia Estelina Naomi Tendean
Department of Biology, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Integrative Network Pharmacology Study of Cordyceps militaris Compounds for Prostate Cancer Treatment Sarah Cecilia Astrid Laihad; Trina Ekawati Tallei; Lydia Estelina Naomi Tendean; Grace Lendawati Amelia Turalaki; Sylvia Ritta Marunduh; Diana Shintawati Purwanto; Billy Johnson Kepel; Abdul Hawil Abas
Heca Journal of Applied Sciences Vol. 4 No. 1 (2026): March 2026
Publisher : Heca Sentra Analitika

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.60084/hjas.v4i1.382

Abstract

Prostate cancer remains one of the leading causes of cancer-related mortality in men, while adverse effects and the development of drug resistance often limit current therapeutic strategies. Natural products have gained increasing attention as potential sources of novel anticancer agents due to their multitarget properties and relatively low toxicity. Cordyceps militaris, a medicinal fungus rich in bioactive compounds, has been reported to exhibit anticancer activity; however, its compound-target interactions in prostate cancer have not been comprehensively elucidated. This study aimed to explore the interactions between C. militaris bioactive compounds and prostate cancer-associated targets using a pharmacology network-based in silico approach. A total of 50 bioactive compounds were collected from metabolite profiling studies, of which 19 compounds were selected based on high predicted TP53 expression enhancer activity (Pa ≥ 0.7) using WAY2DRUG PASS analysis. Protein targets were predicted using SwissTargetPrediction and the Similarity Ensemble Approach, and then intersected with prostate cancer-associated proteins retrieved from GEPIA2, GeneCards, and OMIM, yielding 499 overlapping targets. Protein interaction network analysis was performed using STRING and visualized in Cytoscape, enabling the identification of key hub proteins based on the applied parameters, highlighting ten key proteins, including SRC, ESR1, MAPK1, AKT1, HSP90AA1, MAPK3, HSP90AB1, EGFR, GRB2, and PRKACA, within the interaction network. Pathway enrichment analysis indicated that these targets were predominantly involved in cancer-associated signaling pathways, such as the EGFR tyrosine kinase inhibitor resistance pathway. Furthermore, the results revealed that the selected compounds interact with these key prostate cancer-associated proteins. Pharmacokinetic and toxicity evaluation predicted favorable drug-likeness and acceptable safety profiles for selected compounds. Overall, this study highlights the potential of C. militaris bioactive compounds as promising alternative for prostate cancer through multitarget modulation of clinically relevant signaling pathways. Further experimental validation is still required to confirm these findings.
Mechanistic Exploration of Moringa oleifera Leaf Bioactives in Prostate Cancer Using Network Pharmacology Feniea Wulan Agaype Tengke; Trina Ekawati Tallei; Grace Lendawati Amelia Turalaki; Lydia Estelina Naomi Tendean; Martha Marie Kaseke; Nurdjannah Jane Niode; Fatimawali Fatimawali
Grimsa Journal of Science Engineering and Technology Vol. 4 No. 1 (2026): April 2026
Publisher : Graha Primera Saintifika

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61975/gjset.v4i1.105

Abstract

Prostate cancer remains one of the most prevalent malignancies in men worldwide, while current therapeutic strategies are often associated with adverse effects and the emergence of drug resistance, highlighting the need for safer and more effective alternatives. This study aimed to elucidate the multitarget molecular mechanisms of bioactive compounds derived from Moringa oleifera leaves against prostate cancer using an integrated in silico network pharmacology approach. A total of 137 bioactive compounds were collected from LC–MS/MS profiling data and phytochemical databases, of which 20 compounds with high predicted biological activity were prioritized based on Way2Drug PASS analysis. Potential protein targets were predicted and intersected with prostate cancer–associated genes to identify shared targets. Protein–protein interaction network analysis revealed 536 overlapping targets, with ten hub proteins, ESR1, AKT1, SRC, EGFR, TP53, HSP90AA1, PIK3CA, HSP90AB1, PIK3R1, and MAPK1, identified as central nodes. Pathway enrichment analysis demonstrated that these targets were predominantly involved in cancer-related signaling pathways, including pathways associated with EGFR tyrosine kinase inhibitor resistance. Pharmacokinetic and toxicity assessments indicated that several compounds, such as isorhamnetin, kaempferol, tocopherol, and afzelin, exhibited favorable drug-likeness properties and low predicted toxicity. Overall, these findings suggest that bioactive compounds from Moringa oleifera leaves exert anticancer effects through a multitarget and multi pathway mode of action rather than single-protein modulation. This study provides systematic insight into the molecular mechanisms underlying the anti–prostate cancer potential of Moringa oleifera leaves and supports their relevance as candidates for further experimental validation and drug development.